RAC 2.20% $1.78 race oncology ltd

Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-83

  1. 552 Posts.
    lightbulb Created with Sketch. 93
    Which peers are you comparing to?

    What would be a reasonable valuation in your eyes, and what evidence would you use to support that?

 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.